Display options
Cite
Blethen KE, Arsiwala TA, Fladeland RA, et al. Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. Neurooncol Adv. 2021;3:v133-v143doi: 10.1093/noajnl/vdab123.
Blethen, K. E., Arsiwala, T. A., Fladeland, R. A., Sprowls, S. A., Panchal, D. M., Adkins, C. E., Kielkowski, B. N., Earp, L. E., Glass, M. J., Pritt, T. A., Cabuyao, Y. M., Aulakh, S., & Lockman, P. R. (2021). Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. Neuro-oncology advances, 3v133-v143. https://doi.org/10.1093/noajnl/vdab123
Blethen, Kathryn E, et al. "Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases." Neuro-oncology advances vol. 3 (2021): v133-v143. doi: https://doi.org/10.1093/noajnl/vdab123
Blethen KE, Arsiwala TA, Fladeland RA, Sprowls SA, Panchal DM, Adkins CE, Kielkowski BN, Earp LE, Glass MJ, Pritt TA, Cabuyao YM, Aulakh S, Lockman PR. Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. Neurooncol Adv. 2021 Nov 27;3:v133-v143. doi: 10.1093/noajnl/vdab123. eCollection 2021 Nov. PMID: 34859240; PMCID: PMC8633736.
Copy Download .nbib Format: NLM
Share it on

Neurooncol Adv. 2021 Nov 27;3:v133-v143. doi: 10.1093/noajnl/vdab123. eCollection 2021 Nov.

Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases.

Neuro-oncology advances

Kathryn E Blethen, Tasneem A Arsiwala, Ross A Fladeland, Samuel A Sprowls, Dhruvi M Panchal, Chris E Adkins, Brooke N Kielkowski, Leland E Earp, Morgan J Glass, Trenton A Pritt, Yssabela M Cabuyao, Sonikpreet Aulakh, Paul R Lockman

Affiliations

  1. Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia, USA.
  2. Department of Chemical and Biomedical Engineering, Benjamin M. Statler College of Engineering and Mineral Resources, West Virginia University, Morgantown, West Virginia, USA.
  3. Department of Pharmaceutical Sciences, School of Pharmacy, South University, Savannah, Georgia, USA.
  4. Department of Cancer Cell Biology, School of Medicine, West Virginia University, Morgantown, West Virginia, USA.

PMID: 34859240 PMCID: PMC8633736 DOI: 10.1093/noajnl/vdab123

Abstract

The blood-brain barrier is the selectively permeable vasculature of the brain vital for maintaining homeostasis and neurological function. Low permeability is beneficial in the presence of toxins and pathogens in the blood. However, in the presence of metastatic brain tumors, it is a challenge for drug delivery. Although the blood-tumor barrier is slightly leaky, it still is not permissive enough to allow the accumulation of therapeutic drug concentrations in brain metastases. Herein, we discuss the differences between primary brain tumors and metastatic brain tumors vasculature, effects of therapeutics on the blood-tumor barrier, and characteristics to be manipulated for more effective drug delivery.

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Keywords: blood-brain barrier; brain metastases; breast cancer; drug delivery

References

  1. J Cereb Blood Flow Metab. 1997 Nov;17(11):1239-53 - PubMed
  2. Lancet Oncol. 2002 Jan;3(1):53-7 - PubMed
  3. Clin Cancer Res. 2003 Jul;9(7):2849-55 - PubMed
  4. Colloids Surf B Biointerfaces. 2016 May 1;141:260-267 - PubMed
  5. J Pharmacol Exp Ther. 1994 Apr;269(1):22-7 - PubMed
  6. Int J Nanomedicine. 2020 Aug 03;15:5491-5501 - PubMed
  7. Mol Pharm. 2017 Nov 6;14(11):3834-3847 - PubMed
  8. Cancer Lett. 2021 Apr 1;502:166-179 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1487-95 - PubMed
  10. Cell Stem Cell. 2014 Mar 6;14(3):357-69 - PubMed
  11. Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):860-6 - PubMed
  12. Neurobiol Dis. 2010 Jan;37(1):13-25 - PubMed
  13. Am J Pathol. 2010 Jun;176(6):2958-71 - PubMed
  14. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71 - PubMed
  15. Adv Pharm Bull. 2017 Sep;7(3):339-348 - PubMed
  16. J Neurooncol. 2013 May;112(3):461-6 - PubMed
  17. Nat Rev Clin Oncol. 2020 May;17(5):279-299 - PubMed
  18. Oncology. 2003;64(1):28-35 - PubMed
  19. J Control Release. 2019 Jun 10;303:117-129 - PubMed
  20. Clin Cancer Res. 2009 Oct 1;15(19):6148-57 - PubMed
  21. Trends Neurosci. 2019 Oct;42(10):667-679 - PubMed
  22. Neurooncol Adv. 2020 Jun 30;2(1):vdaa071 - PubMed
  23. Oncotarget. 2017 Jul 26;8(48):83734-83744 - PubMed
  24. J Cell Biol. 1997 Aug 25;138(4):877-89 - PubMed
  25. PLoS One. 2014 Jan 08;9(1):e82331 - PubMed
  26. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  27. Pharmacol Res. 2018 Jun;132:47-68 - PubMed
  28. Nat Rev Clin Oncol. 2019 Aug;16(8):469-493 - PubMed
  29. Adv Exp Med Biol. 1980;131:307-19 - PubMed
  30. J Clin Oncol. 2002 Sep 1;20(17):3644-50 - PubMed
  31. AAPS J. 2015 Jul;17(4):802-12 - PubMed
  32. NMR Biomed. 2012 May;25(5):726-36 - PubMed
  33. BMC Cancer. 2020 Apr 7;20(1):292 - PubMed
  34. Cell Mol Neurobiol. 2000 Apr;20(2):131-47 - PubMed
  35. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64 - PubMed
  36. J Neurooncol. 1988 Sep;6(2):157-68 - PubMed
  37. Pharm Res. 2018 Jul 12;35(9):177 - PubMed
  38. Biochemistry (Mosc). 2019 Jul;84(7):762-772 - PubMed
  39. Surg Oncol. 2012 Sep;21(3):e143-51 - PubMed
  40. PLoS One. 2016 Feb 24;11(2):e0148613 - PubMed
  41. BMC Cancer. 2018 Dec 7;18(1):1225 - PubMed
  42. J Cereb Blood Flow Metab. 2012 Nov;32(11):1959-72 - PubMed
  43. Oncotarget. 2016 Nov 29;7(48):79401-79407 - PubMed
  44. Drug Metab Dispos. 2014 Aug;42(8):1292-300 - PubMed
  45. Am J Pathol. 1992 Nov;141(5):1115-24 - PubMed
  46. Theranostics. 2020 May 15;10(14):6122-6135 - PubMed
  47. J Neuropathol Exp Neurol. 2019 Apr 1;78(4):326-339 - PubMed
  48. Biomed Res Int. 2015;2015:320941 - PubMed
  49. Cancer Res. 2017 Jan 15;77(2):238-246 - PubMed
  50. Pharm Res. 2012 Mar;29(3):770-81 - PubMed
  51. Pharm Res. 2016 Dec;33(12):2930-2942 - PubMed
  52. Clin Exp Metastasis. 2000;18(6):481-92 - PubMed
  53. Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80 - PubMed
  54. Clin Cancer Res. 2010 Oct 1;16(19):4892-8 - PubMed
  55. Drug Deliv. 2016 Jun;23(5):1788-98 - PubMed
  56. Front Pharmacol. 2017 Apr 11;8:193 - PubMed
  57. J Cereb Blood Flow Metab. 2017 Oct;37(10):3300-3317 - PubMed
  58. Cell Mol Neurobiol. 2000 Apr;20(2):217-30 - PubMed
  59. Ann Oncol. 2001 Jan;12(1):59-67 - PubMed
  60. Curr Oncol Rep. 2012 Feb;14(1):48-54 - PubMed
  61. Neurol Sci. 2011 Feb;32(1):113-6 - PubMed
  62. Immunol Rev. 2019 Jul;290(1):60-84 - PubMed
  63. Pharm Res. 2009 Nov;26(11):2486-94 - PubMed
  64. Neuroradiology. 2006 Oct;48(10):773-81 - PubMed
  65. Neoplasia. 2021 Jul;23(7):676-691 - PubMed
  66. Lancet Oncol. 2020 May;21(5):655-663 - PubMed
  67. J Pharmacol Exp Ther. 2012 Jul;342(1):33-40 - PubMed
  68. Int J Hyperthermia. 2020 Jul;37(2):35-43 - PubMed
  69. Clin Cancer Res. 2010 Dec 1;16(23):5664-78 - PubMed
  70. Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8717-E8726 - PubMed
  71. Front Cell Neurosci. 2014 Aug 04;8:211 - PubMed
  72. Invest Radiol. 2011 Nov;46(11):718-25 - PubMed
  73. Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):E75-E84 - PubMed
  74. J Physiol. 2000 Oct 1;528 Pt 1:177-87 - PubMed
  75. Clin Exp Metastasis. 2016 Apr;33(4):373-83 - PubMed
  76. Mol Pharm. 2014 Nov 3;11(11):4199-207 - PubMed
  77. J Neurosci Methods. 2013 Sep 30;219(1):188-95 - PubMed
  78. Clin Anat. 2018 Sep;31(6):812-823 - PubMed
  79. N Engl J Med. 2014 Feb 20;370(8):699-708 - PubMed
  80. Ann Oncol. 2011 Nov;22(11):2466-2470 - PubMed
  81. Pharm Res. 2018 Jan 09;35(2):31 - PubMed
  82. Int J Neurosci. 2021 Sep 24;:1-8 - PubMed
  83. Immunotherapy. 2017 Jan;9(2):183-196 - PubMed
  84. Neuro Oncol. 2010 Mar;12(3):233-42 - PubMed
  85. J Clin Invest. 2002 Nov;110(9):1309-18 - PubMed
  86. Anticancer Drugs. 2007 Jan;18(1):23-8 - PubMed
  87. N Engl J Med. 1971 Nov 18;285(21):1182-6 - PubMed
  88. N Engl J Med. 2018 Jan 11;378(2):158-168 - PubMed
  89. Mol Pharm. 2019 Mar 4;16(3):1282-1293 - PubMed
  90. Nat Commun. 2014 Jun 19;5:4196 - PubMed
  91. Cancer Res. 2013 Dec 1;73(23):7079-89 - PubMed
  92. J Control Release. 2012 Nov 10;163(3):277-84 - PubMed
  93. Transl Oncol. 2016 Jun;9(3):219-27 - PubMed
  94. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):934-41 - PubMed
  95. Ann Oncol. 2014 Dec;25(12):2351-2356 - PubMed
  96. J Nucl Med. 2019 Apr;60(4):486-491 - PubMed
  97. Cancer Res. 2000 Sep 1;60(17):4959-67 - PubMed
  98. J Pharmacol Exp Ther. 2011 Jan;336(1):223-33 - PubMed
  99. Mol Pharm. 2012 Nov 5;9(11):3236-45 - PubMed
  100. Radiother Oncol. 1994 Apr;31(1):51-60 - PubMed
  101. Cancer Discov. 2017 Dec;7(12):1404-1419 - PubMed
  102. Bioeng Transl Med. 2018 Nov 05;4(1):30-37 - PubMed
  103. J Nucl Med. 2017 May;58(5):700-705 - PubMed
  104. J Neurosurg. 1999 Feb;90(2):300-5 - PubMed
  105. Pharmaceutics. 2020 Dec 11;12(12): - PubMed
  106. BMC Cancer. 2015 Oct 13;15:685 - PubMed
  107. Nat Rev Cancer. 2019 Mar;19(3):133-150 - PubMed
  108. Nat Rev Cancer. 2016 Feb;16(2):121-6 - PubMed
  109. Mol Neurobiol. 2019 Sep;56(9):6645-6653 - PubMed
  110. Clin Cancer Res. 2010 Apr 15;16(8):2443-9 - PubMed
  111. N Engl J Med. 2018 Aug 23;379(8):722-730 - PubMed
  112. J Cereb Blood Flow Metab. 2008 Feb;28(2):431-8 - PubMed
  113. J Neurooncol. 2005 Feb;71(3):281-6 - PubMed
  114. N Engl J Med. 2014 Feb 20;370(8):709-22 - PubMed
  115. Oncotarget. 2019 Oct 29;10(59):6334-6348 - PubMed
  116. Front Pharmacol. 2013 Nov 04;4:136 - PubMed
  117. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):185-91 - PubMed

Publication Types